Innovent与武田达成了一项价值114亿美元的三款抗癌药交易，武田在美国负责其中一款药物的开发，并在美国市场利润分成40/60。 Innovent and Takeda closed a $11.4B deal for three cancer drugs, with Takeda leading U.S. development of one and sharing profits 40/60 in the U.S.

Innovent Biologics与武田自2025年12月4日起达成全球合作伙伴关系，推进三项癌症治疗方案：IBI363、IBI343及一个IBI3001选项。 Innovent Biologics and Takeda have closed a global partnership effective December 4, 2025, advancing three cancer therapies: IBI363, IBI343, and an option on IBI3001. Takeda将在美国牵头发展和共同商业化IBI363,而创新者保留大中国的权利。 Takeda will lead development and co-commercialize IBI363 in the U.S., while Innovent retains rights in Greater China. Takeda获得了大中国境外的IBI343的专属权以及全球IBI3001许可权。 Takeda gains exclusive rights outside Greater China for IBI343 and an option to license IBI3001 globally. Innovent 预付款获 12 亿美元，其中包括 1 亿美元的股权，未来里程碑潜力最高可达 102 亿美元，总额达 114 亿美元。 Innovent receives $1.2 billion upfront, including a $100 million equity stake, with potential up to $10.2 billion in milestones, totaling $11.4 billion. 大中国以外地区适用特许权使用费,但美国IBI363除外,该地的利润和损失分化为40/60。 Royalties apply outside Greater China, except in the U.S. for IBI363, where profits and losses are split 40/60.